Overview

An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment

Status:
Enrolling by invitation

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

In June 2021, Chinese Food and Drug Administration approved the launch of the self-developed new drug Tenofovir Amibufenamide(TMF). TMF is a new second generation of tenofovir(TFV) and its effect on blood lipids is unclear. Our study aims to figure out the effect of TMF on serum lipid level in the process of antiviral therapy for chronic hepatitis B patients.

Phase:

N/A

Details

Lead Sponsor:

Wuhan Union Hospital, China

Treatments:

Amlodipine
Amlodipine, atorvastatin drug combination
Atorvastatin
Hypolipidemic Agents
Tenofovir